D.E. Shaw & Co
ESLA icon

D.E. Shaw & Co’s Estrella Immunopharma ESLA Stock Holding History

D.E. Shaw & Co’s Portfolio ESLA Stock Details ESLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-197,000
Closed -$1.95M – 5484
2021
Q3 		$1.95M Buy
+197,000
New +$1.94M ﹤0.01% 3057

Other funds holding ESLA

KIM
Karpus Investment Management Pittsford, New York $3.21B AUM 6.83% 1-Year Est. Return
ASM
ATW SPAC Management New York $79.2M AUM 10.67% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
HHGC
Hunting Hill Global Capital New York $129M AUM 17.34% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return

D.E. Shaw & Co's ESLA Position: Q4 2021 in Review

D.E. Shaw & Co sold out of Estrella Immunopharma (ESLA) in Q4 2021, closing a stake of 197,000 shares — an estimated $1.95M sold.

D.E. Shaw & Co first reported a position in ESLA in Q3 2021 and held it in 1 quarter. The position peaked at $1.95M in Q3 2021. 19 funds tracked by Wall St. Rank hold ESLA as of Q4 2021.

  • D.E. Shaw & Co reported no remaining Estrella Immunopharma position as of Q4 2021 after selling out during the quarter.
  • D.E. Shaw & Co sold 197,000 Estrella Immunopharma shares in Q4 2021, an estimated $1.95M.
  • D.E. Shaw & Co first reported a position in Estrella Immunopharma in Q3 2021 and held it in 1 quarter.
  • D.E. Shaw & Co's Estrella Immunopharma position peaked at $1.95M in Q3 2021.
  • 19 funds tracked by Wall St. Rank held Estrella Immunopharma as of Q4 2021.

Based on D.E. Shaw & Co's 13F filing for Q4 2021, filed 14 Feb 2022.